Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real-world study in Taiwan

被引:16
作者
Chang, Po-Cheng [1 ,2 ]
Wang, Chun-Li [1 ,2 ]
Hsiao, Fu-Chih [1 ,2 ]
Wen, Ming-Shien [1 ,2 ]
Huang, Chien-Ying [1 ,2 ]
Chou, Chung-Chuan [1 ,2 ]
Chu, Pao-Hsien [1 ,2 ]
机构
[1] Chang Gung Mem Hosp, Dept Internal Med, Div Cardiol, Linkou, Taiwan
[2] Chang Gung Univ, Sch Med, 5 Fu Xing St, Taoyuan 33305, Taiwan
关键词
Heart failure; Sacubitril; valsartan (LCZ696); Angiotensin receptor blockers; NEPRILYSIN INHIBITOR; ENALAPRIL; VALSARTAN;
D O I
10.1002/ehf2.12924
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims This study aimed to compare the efficacy of angiotensin receptor-neprilysin inhibitor (ARNI) therapy with angiotensin receptor blocker (ARB) therapy for cardiovascular outcomes in patients with heart failure (HF) with reduced ejection fraction. Methods and results Data were obtained from the Chang Gung Research Database. The cohort entry date of the ARB group was assigned as that of the ARNI group to avoid immortal time bias. Additionally, 1:1 propensity score matching based on age, sex, and baseline left ventricular ejection fraction was conducted. The expectation-maximization imputation method with inverse probability of treatment weighting was used to compare outcomes between the two groups. The primary outcome was a composite of cardiovascular death and hospitalization for worsening HF. Patients who received ARNI therapy had a significantly lower risk of the primary composite outcome occurring than patients who received ARBs (hazard ratio, 0.74; 95% confidence interval, 0.57-0.96). The reduction of hospitalization for worsening HF contributed most to the primary outcome benefits. In addition to the primary outcome, the ARNI group had a significantly lower risk of non-fatal myocardial infarction. The improvement of ejection fraction was not significantly different between the groups. The medication doses of ARNI were lower than in clinical trials. Conclusions In patients with HF with reduced ejection fraction, sacubitril/valsartan was superior to ARB therapy in reducing the occurrence of the primary outcome endpoint of hospitalization for worsening HF and cardiovascular death.
引用
收藏
页码:3003 / 3012
页数:10
相关论文
共 18 条
[1]   Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation [J].
Chang, Hung-Yu ;
Feng, An-Ning ;
Fong, Man-Cai ;
Hsueh, Chao-Wen ;
Lai, Wei-Tsung ;
Huang, Kuan-Chih ;
Chong, Eric ;
Chen, Chi-Nan ;
Chang, Hung-Chuan ;
Yin, Wei-Hsian .
JOURNAL OF CARDIOLOGY, 2019, 74 (3-4) :372-380
[2]   A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure [J].
Cohn, JN ;
Tognoni, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (23) :1667-1675
[3]   Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients [J].
Desai, Akshay S. ;
McMurray, John J. V. ;
Packer, Milton ;
Swedberg, Karl ;
Rouleau, Jean L. ;
Chen, Fabian ;
Gong, Jianjian ;
Rizkala, Adel R. ;
Brahimi, Abdel ;
Claggett, Brian ;
Finn, Peter V. ;
Hartley, Loren Howard ;
Liu, Jiankang ;
Lefkowitz, Martin ;
Shi, Victor ;
Zile, Michael R. ;
Solomon, Scott D. .
EUROPEAN HEART JOURNAL, 2015, 36 (30) :1990-1997
[4]   Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction [J].
Greene, Stephen J. ;
Fonarow, Gregg C. ;
DeVore, Adam D. ;
Sharma, Puza P. ;
Vaduganathan, Muthiah ;
Albert, Nancy M. ;
Duffy, Carol, I ;
Hill, Larry ;
McCague, Kevin ;
Patterson, J. Herbert ;
Spertus, John A. ;
Thomas, Laine ;
Williams, Fredonia B. ;
Hernandez, Adrian F. ;
Butler, Javed .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (19) :2365-2383
[5]   Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan [J].
Hsiao, Fu-Chih ;
Wang, Chun-Li ;
Chang, Po-Cheng ;
Lu, Yu-Ying ;
Huang, Chien-Ying ;
Chu, Pao-Hsien .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2020, 25 (02) :152-157
[6]   Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial [J].
Konstam, Marvin A. ;
Neaton, James D. ;
Dickstein, Kenneth ;
Drexler, Helmut ;
Komajda, Michel ;
Martinez, Felipe A. ;
Riegger, Gunter A. J. ;
Malbecq, William ;
Smith, Ronald D. ;
Guptha, Soneil ;
Poole-Wilson, Philip A. .
LANCET, 2009, 374 (9704) :1840-1848
[7]   Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure [J].
Luzier, AB ;
Forrest, A ;
Adelman, M ;
Hawari, FI ;
Schentag, JJ ;
Izzo, JL .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (04) :465-469
[8]   Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure [J].
McMurray, John J. V. ;
Packer, Milton ;
Desai, Akshay S. ;
Gong, Jianjian ;
Lefkowitz, Martin P. ;
Rizkala, Adel R. ;
Rouleau, Jean L. ;
Shi, Victor C. ;
Solomon, Scott D. ;
Swedberg, Karl ;
Zile, Michael R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11) :993-1004
[9]   The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF [J].
Mogensen, Ulrik M. ;
Kober, Lars ;
Kristensen, Soren L. ;
Jhund, Pardeep S. ;
Gong, Jianjian ;
Lefkowitz, Martin P. ;
Rizkala, Adel R. ;
Rouleau, Jean L. ;
Shi, Victor C. ;
Swedberg, Karl ;
Zile, Michael R. ;
Solomon, Scott D. ;
Packer, Milton ;
McMurray, John J. V. .
AMERICAN HEART JOURNAL, 2017, 188 :35-41
[10]   Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both [J].
Pfeffer, MA ;
McMurray, JJV ;
Velazquez, EJ ;
Rouleau, JL ;
Kober, L ;
Maggioni, AP ;
Solomon, SD ;
Swedberg, K ;
Van de Werf, F ;
White, H ;
Leimberger, JD ;
Henis, M ;
Edwards, S ;
Zelenkofske, S ;
Sellers, MA ;
Califf, RM ;
Aylward, P ;
Armstrong, P ;
Barvik, S ;
Belenkov, Y ;
Dalby, A ;
Diaz, R ;
Drexler, H ;
Ertl, G ;
Francis, G ;
Hampton, J ;
Harsanyi, A ;
Kvasnicka, J ;
Mareev, V ;
Marin-Neto, J ;
Murin, J ;
Myers, M ;
Nordlander, R ;
Opolski, G ;
Soler-Soler, J ;
Spac, J ;
Stefenelli, T ;
Sugrue, D ;
Van Gilst, W ;
Varshavsky, S ;
Weaver, D ;
Zannad, F ;
Aguilar, D ;
Alvarez, A ;
Al-Taweel, M ;
Anavekar, N ;
Finn, P ;
Lopez-Jimenez, F ;
Mercier, R ;
Lewis, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (20) :1893-1906